Shareholder rights law firm Johnson & Weaver, LLP has commenced an
investigation into whether certain officers and directors of Provectus
Biopharmaceuticals, Inc. (NYSE: PVCT) violated state or federal laws.
On May 20, 2014, TheStreet.com published an article stating that
Provectus had originally described its PV-10 drug as a "breakthrough
cancer drug" on its website. Subsequently, the drug description on the
website was changed to "an investigational drug for cancer."
On May 21, 2014, an article published by Seeking Alpha cited that
"PVCT is connected to questionable paid stock promoters whose other
recommendations have recently been halted by the SEC". The article
continued that "PV10 has no Phase 3 trial in sight while patents begin
expiring in 2016 and appears to have failed their FDA Breakthrough
Since the release of the above articles, PVCT shares have fallen over
24% in trading. On May 23, 2014, trading in Provectus' stock was halted
at $2.02 per share.
If you are a Provectus shareholder and are interested in learning
more about the investigation or your legal rights and remedies, please
contact Jim Baker (email@example.com)
at 619-814-4471. If you email, please include your phone number.
Johnson & Weaver, LLP is a nationally recognized shareholder rights law
firm with offices in California and New York. The firm represents
individual and institutional investors in shareholder derivative and
securities class action lawsuits. For more information about the firm
and its attorneys, please visit http://www.johnsonandweaver.com.
Attorney advertising. Past results do not guarantee future outcomes.
[ Back To NFVZone's Homepage ]